As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

Merck has become the latest drugmaker to limit discounts on 340B drugs, saying it will stop giving 340B discounts on certain drugs unless hospitals provide claims data. The drugmaker sent a letter Aug ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

A Kansas bill, SB 284, is being considered to support rural hospitals through the 340B drug discount program. The 340B program requires drug companies to sell medications at a discount to certain ...

The 340B drug discount program has followed a familiar health policy trajectory. An intervention that was supposed to ease cost pressures, it instead is producing cascading unintended consequences ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...

The Kansas Legislature is currently considering a bill, SB 284, under seemingly noble pretense. Proponents of SB 284 argue that its 340B provisions are needed to support rural hospitals and their ...